November 18, 2018 – By Ashley Edward
Salzhauer Michael decreased Jpmorgan Chase & Co (JPM) stake by 62.59% reported in 2018Q2 SEC filing. Salzhauer Michael sold 54,011 shares as Jpmorgan Chase & Co (JPM)’s stock rose 2.83%. The Salzhauer Michael holds 32,289 shares with $3.37M value, down from 86,300 last quarter. Jpmorgan Chase & Co now has $365.71 billion valuation. The stock decreased 0.07% or $0.08 during the last trading session, reaching $109.99. About 13.80M shares traded. JPMorgan Chase & Co. (NYSE:JPM) has risen 24.41% since November 18, 2017 and is uptrending. It has outperformed by 8.79% the S&P500. Some Historical JPM News: 26/04/2018 – ANTHEM INC ANTM.N : JP MORGAN RAISES TARGET PRICE TO $287 FROM $261; 16/03/2018 – JPMORGAN CHASE & CO JPM.N : CREDIT SUISSE RAISES TARGET PRICE TO $127 FROM $125; RATING OUTPERFORM; 19/04/2018 – JPMORGAN CHASE & CO JPM.N – COMMITTING $4.5 BLN FOR REGIONAL HOME AND SMALL BUSINESS LENDING AND AFFORDABLE RENTAL HOUSING; 14/05/2018 – PayPal Presenting at JPMorgan Conference Tomorrow; 20/04/2018 – The platform was built over more than a year using Quorum, a type of open-source blockchain that JPMorgan has developed inhouse; 07/05/2018 – Dimon Hopeful Trade Tensions Won’t Derail JPMorgan’s China Plans; 27/03/2018 – LULULEMON ATHLETICA INC LULU.O : JP MORGAN RAISES TARGET PRICE TO $95 FROM $92; 09/03/2018 – JPMORGAN ECM EXECUTIVE DIRECTOR WU IS SAID TO BE LEAVING BANK; 13/04/2018 – JP Morgan Chase, Citigroup, Wells Faro and PNC all saw share prices fall; 13/04/2018 – JPMorgan Chase Sees 2018 Adjusted Expense About $63B
Orbimed Advisors Llc decreased Gw Pharmaceuticals Plc (GWPH) stake by 71.62% reported in 2018Q2 SEC filing. Orbimed Advisors Llc sold 53,000 shares as Gw Pharmaceuticals Plc (GWPH)’s stock declined 7.24%. The Orbimed Advisors Llc holds 21,000 shares with $2.93M value, down from 74,000 last quarter. Gw Pharmaceuticals Plc now has $4.28B valuation. The stock increased 1.50% or $1.96 during the last trading session, reaching $132.3. About 408,176 shares traded. GW Pharmaceuticals plc (NASDAQ:GWPH) has risen 29.17% since November 18, 2017 and is uptrending. It has outperformed by 13.55% the S&P500. Some Historical GWPH News: 19/04/2018 – The medication, which is manufactured by GW Pharmaceuticals, is used in the treatment of seizures associated with childhood epilepsy; 19/04/2018 – GW Pharma walks away from adcomm with unanimous support for anti-seizure med. An OK shouldn’t take long now $GWPH; 19/04/2018 – I can’t recall ever seeing such a complete lineup signaling an FDA OK. Insider recommendation saying approve it, unanimous panel support, commitment from regulators to accelerate, no hint of hesitation. It is remarkable; 19/04/2018 – Epilepsy Foundation Testifies Before FDA Advisory Committee in Support of Potential First-Ever Cannabidiol Drug to Treat Dravet; 16/05/2018 – GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences Announce Publication in The New England Journal of Medicine of a P; 16/03/2018 – HQGE Unveils Extensive Cannabidiol (CBD Oil) Database, Teams with Hemp, Inc. to Produce and Distribute High-Quality Customizabl; 19/04/2018 – GW PHARMACEUTICALS PLC – PDUFA GOAL DATE FOR COMPLETION OF NDA REVIEW OF THE CANNABIDIOL ORAL SOLUTION EPIDIOLEX IS JUNE 27, 2018; 17/04/2018 – GW cannabis-derived epilepsy drug gets positive FDA staff review; 16/05/2018 – Cannabidiol Significantly Reduces Seizures in Patients with Severe Form of Epilepsy; 13/03/2018 – GW Pharmaceuticals Announces Receipt of Notices of Allowance by the United States Patent and Trademark Office (USPTO) for Five New Epidiolex® (cannabidiol) Patents
Analysts await GW Pharmaceuticals plc (NASDAQ:GWPH) to report earnings on December, 3. They expect $-2.39 EPS, down 9.63% or $0.21 from last year’s $-2.18 per share. After $-1.26 actual EPS reported by GW Pharmaceuticals plc for the previous quarter, Wall Street now forecasts 89.68% negative EPS growth.
Among 6 analysts covering GW Pharma (NASDAQ:GWPH), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. GW Pharma had 7 analyst reports since June 25, 2018 according to SRatingsIntel. The firm earned “Buy” rating on Tuesday, June 26 by Bank of America. Morgan Stanley maintained it with “Overweight” rating and $197 target in Friday, September 7 report. The rating was initiated by Goldman Sachs with “Buy” on Tuesday, June 26. As per Thursday, October 11, the company rating was maintained by Morgan Stanley. Cantor Fitzgerald maintained it with “Buy” rating and $23500 target in Monday, June 25 report.
More notable recent GW Pharmaceuticals plc (NASDAQ:GWPH) news were published by: Benzinga.com which released: “4 Reasons Why Leerink Is Bullish On GW Pharma” on November 14, 2018, also Seekingalpha.com with their article: “Leerink sees 34% upside in Allergan in premarket analyst action” published on November 13, 2018, Nasdaq.com published: “Why GW Pharmaceuticals Stock Dropped 20% in October” on November 10, 2018. More interesting news about GW Pharmaceuticals plc (NASDAQ:GWPH) were released by: Benzinga.com and their article: “Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week” published on November 17, 2018 as well as Fool.com‘s news article titled: “Better Buy: GW Pharmaceuticals PLC vs. 22nd Century Group Inc.” with publication date: October 21, 2018.
Orbimed Advisors Llc increased Teleflex Inc (NYSE:TFX) stake by 73,400 shares to 190,400 valued at $51.07 million in 2018Q2. It also upped Dentsply Sirona Inc stake by 2.17 million shares and now owns 2.39 million shares. Deciphera Pharmaceuticals In was raised too.
Among 4 analysts covering JPMorgan Chase (NYSE:JPM), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. JPMorgan Chase had 4 analyst reports since July 16, 2018 according to SRatingsIntel. The firm earned “Market Perform” rating on Monday, July 16 by BMO Capital Markets. The firm earned “Buy” rating on Thursday, July 19 by DZ Bank. The stock of JPMorgan Chase & Co. (NYSE:JPM) earned “Buy” rating by Bank of America on Monday, September 17. The stock of JPMorgan Chase & Co. (NYSE:JPM) has “Neutral” rating given on Wednesday, September 26 by Citigroup.
More notable recent JPMorgan Chase & Co. (NYSE:JPM) news were published by: Fool.com which released: “Why Did Berkshire Hathaway Buy JPMorgan Chase Stock?” on November 18, 2018, also Investorplace.com with their article: “5 Top Stock Trades for Friday: JPMorgan, JC Penney and Walmart” published on November 15, 2018, Fool.com published: “3 Top Bank Stocks to Buy in November” on November 18, 2018. More interesting news about JPMorgan Chase & Co. (NYSE:JPM) were released by: Streetinsider.com and their article: “Warren Buffett’s Berkshire Enters JPMorgan (JPM), Oracle (ORCL), Adds to (AAPL) (more…)” published on November 14, 2018 as well as Fool.com‘s news article titled: “Top Stocks Warren Buffett Just Bought” with publication date: November 16, 2018.
Investors sentiment increased to 0.99 in Q2 2018. Its up 0.18, from 0.81 in 2018Q1. It is positive, as 51 investors sold JPM shares while 741 reduced holdings. 112 funds opened positions while 669 raised stakes. 2.34 billion shares or 2.08% less from 2.39 billion shares in 2018Q1 were reported. 904,603 are owned by Bradley Foster And Sargent Inc Ct. Terril Brothers Incorporated holds 48,757 shares or 1.56% of its portfolio. Selway Asset has 3.27% invested in JPMorgan Chase & Co. (NYSE:JPM). Eos Mngmt Lp stated it has 0.65% in JPMorgan Chase & Co. (NYSE:JPM). Vaughan Nelson Management LP holds 15,245 shares or 0.02% of its portfolio. Hollow Brook Wealth Mgmt holds 0.74% or 9,031 shares in its portfolio. Cetera Advsr Ltd Liability Company reported 63,502 shares. Cooke & Bieler LP holds 1.7% or 908,933 shares in its portfolio. Fil Ltd holds 0.73% or 4.64M shares. Meristem Limited Liability Partnership holds 6,319 shares or 0.23% of its portfolio. Endurance Wealth Inc holds 2.23% or 129,872 shares in its portfolio. Hall Laurie J Trustee has 9,842 shares for 0.59% of their portfolio. Reinhart Ptnrs Inc reported 5,950 shares stake. Bourgeon Cap Management Ltd holds 73,958 shares. Round Table Serv Limited Liability Corp invested 0.34% in JPMorgan Chase & Co. (NYSE:JPM).
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.